Differential Site-Based Expression of Pentose Phosphate Pathway-Related Proteins among Breast Cancer Metastases

Table 5

Multivariate Cox analysis of the association between expression levels of pentose phosphate pathway-related proteins in metastatic breast cancers and overall survival.

Included parameters	Bone metastasis			Lung metastasis
	Overall survival			Overall survival
	HR	95% CI	value	HR	95% CI	value
ER status
Negative versus positive	1.768	0.113–27.61	0.685	n/a	n/a	n/a
PR status
Negative versus positive	0.453	0.119–1.730	0.247	n/a	n/a	n/a
HER-2 status
Negative versus positive	1.025	0.217–4.833	0.975	n/a	n/a	n/a
Ki-67 LI
≤14 versus >14	0.961	0.031–29.98	0.982	11.853	1.841–76.30	0.009
Molecular subtype
TNBC versus non-TNBC	0.647	0.002–254.8	0.886	n/a	n/a	n/a
6PGL
Negative versus positive	4.180	1.160–15.06	0.029	n/a	n/a	n/a
6PGDH
Negative versus positive	n/a	n/a	n/a	1.362	0.130–14.29	0.797

HR, hazard ratio; CI, confidential interval; ER, estrogen receptor; n/a, not applicable; PR, progesterone receptor; HER-2, human epidermal growth factor-2; LI, labeling index; TNBC, triple negative breast cancer; 6PGL, 6-phosphogluconolactonase; n/a, not applicable; 6PGDH, 6-phosphogluconate dehydrogenase.